NHS NEL
Demonstration Formulary
Demonstration Formulary
3 Respiratory system
03-04-03 Anaphylaxis
| Adrenaline / Epinephrine Emerade® |
|
Formulary
|
There has been a patient-level recall of Emerade 500 micrograms pens. This follows earlier recalls for Emerade 150 and 300 microgram pens. (18 May 2020) Supplies of Emerade will therefore no longer be available in the UK until technical issues with the pen are resolved. MHRA - Advice for patients with an Emerade 500 microgram auto-injector letter |
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE CG134: Anaphylaxis
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
- NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema
- NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation